Which company produces acalatinib/acalatinib?

Acalabrutinib/Acalabrutinib, this innovative drug, originated from the in-depth research and development of Acerta Pharma. Acerta Pharma, as the world's leading biopharmaceutical company, focuses on research and innovation in the field of tumor treatment and is committed to providing patients with more advanced and efficient treatment options.

In December 2015, Astra Zeneca, a multinational pharmaceutical giant headquartered in the United Kingdom, realized the huge potential of acotinib. After the drug was approved in the United States and Europe and showed commercial prospects, it successfully acquired Acerta Pharma, thus acquiring the global R&D and commercialization rights of acotinib.

In the EU, acotinib has been widely approved for the treatment of chronic lymphocytic leukemia (CLL), showing significant therapeutic effects whether as monotherapy or in combination with obinutuzumab. It is also used in some countries to treat adults with mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL).

The core mechanism of acalabrutinib lies in its active ingredient acalabrutinib can effectively block Bruton tyrosine kinase, an enzyme critical for B cell survival and growth. By inhibiting the activity of this enzyme, acotinib can slow down the proliferation of cancer cells, thereby curbing the progression of cancer.

As a prescription drug, acotinib must be used under the guidance of a doctor with experience in cancer treatment. The standard dosage regimen is 100 mg twice daily, taken in the form of oral capsules. Treatment can be continued as long as the patient's condition is under control and no unacceptable side effects occur. Of course, if serious side effects occur or other necessary medications are required, the doctor may adjust the treatment plan, including interrupting, stopping treatment, or adjusting the dose of the medication.